- Home
- TYRA vs LYTS Comparison
TYRA vs LYTS Comparison
Compare TYRA & LYTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- LYTS
- Stock Information
- Founded
- TYRA 2018
- LYTS 1976
- Country
- TYRA United States
- LYTS United States
- Employees
- TYRA N/A
- LYTS N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- LYTS Building Products
- Sector
- TYRA Health Care
- LYTS Consumer Discretionary
- Exchange
- TYRA Nasdaq
- LYTS Nasdaq
- Market Cap
- TYRA 681.7M
- LYTS 700.9M
- IPO Year
- TYRA 2021
- LYTS N/A
- Fundamental
- Price
- TYRA $13.39
- LYTS $21.70
- Analyst Decision
- TYRA Strong Buy
- LYTS Strong Buy
- Analyst Count
- TYRA 7
- LYTS 2
- Target Price
- TYRA $30.71
- LYTS $27.50
- AVG Volume (30 Days)
- TYRA 185.2K
- LYTS 207.9K
- Earning Date
- TYRA 11-06-2025
- LYTS 11-06-2025
- Dividend Yield
- TYRA N/A
- LYTS 0.91%
- EPS Growth
- TYRA N/A
- LYTS N/A
- EPS
- TYRA N/A
- LYTS 0.79
- Revenue
- TYRA N/A
- LYTS $573,377,000.00
- Revenue This Year
- TYRA N/A
- LYTS $5.91
- Revenue Next Year
- TYRA N/A
- LYTS $8.03
- P/E Ratio
- TYRA N/A
- LYTS $27.73
- Revenue Growth
- TYRA N/A
- LYTS 22.09
- 52 Week Low
- TYRA $6.42
- LYTS $13.77
- 52 Week High
- TYRA $29.60
- LYTS $25.50
- Technical
- Relative Strength Index (RSI)
- TYRA 59.58
- LYTS 40.28
- Support Level
- TYRA $12.98
- LYTS $23.11
- Resistance Level
- TYRA $13.92
- LYTS $23.85
- Average True Range (ATR)
- TYRA 0.62
- LYTS 0.66
- MACD
- TYRA 0.00
- LYTS -0.28
- Stochastic Oscillator
- TYRA 55.66
- LYTS 3.52
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About LYTS LSI Industries Inc.
LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.